文献速递消化道肿瘤与早癌

分子谱分析为结直肠癌的靶向治疗、免疫治疗及预后提供临床见解

Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis.
PubMed 文献 · Gastroenterology · 2023-05-03

本研究前瞻性对869例中国结直肠癌患者的肿瘤进行大 panel 测序,评估单基因体细胞突变及共突变事件的临床意义,并结合免疫评分、多重免疫染色、全外显子组测序、转录组和单细胞测序分析不同基因组背景下的肿瘤免疫微环境异质性。结果显示 BRAF 或 RBM10 单基因突变与转移性结直肠癌更短的无进展生存期相关,KRAS/AMER1 或 KRAS/APC 共突变者无进展生存期差且未从贝伐珠单抗获益,40例(4.6%)携带 DNA 损伤修复通路致病或可能致病胚系变异。

要点

  • BRAF 或 RBM10 单基因体细胞突变与转移性结直肠癌更短的无进展生存期相关,功能研究提示 RBM10 在结直肠癌发生中起抑癌作用。
  • KRAS/AMER1 或 KRAS/APC 共突变在转移队列中富集,无进展生存期差,且因药物代谢加速未从贝伐珠单抗获益。
  • 40例(4.6%)携带 DNA 损伤修复通路致病或可能致病胚系变异,其中37.5%的肿瘤存在杂合性丢失或双等位基因改变的二次打击事件。

核心结论

  • 整合分析为结直肠癌的预后分层、药物反应及个性化基因组指导的靶向和免疫治疗提供了见解。

研究设计与样本

  • 前瞻性对869例中国结直肠癌患者的肿瘤进行大 panel 测序,评估单基因体细胞突变和共突变事件的临床意义、功能效应及致瘤机制,并联合免疫评分、多重免疫染色、全外显子组测序、转录组和单细胞测序系统评估不同基因组背景下肿瘤免疫微环境的异质性。

主要发现

  • BRAF 或 RBM10 单基因体细胞突变与转移性结直肠癌患者更短的无进展生存期相关,功能研究提示 RBM10 在结直肠癌发生中起抑癌作用。
  • KRAS/AMER1 或 KRAS/APC 共突变在转移队列中富集,该组无进展生存期差,且因药物代谢加速未从贝伐珠单抗获益。
  • 40例(4.6%)携带 DNA 损伤修复通路致病或可能致病胚系变异,其中37.5%的肿瘤存在杂合性丢失或双等位基因改变的二次打击事件。
  • 高肿瘤插入或缺失负荷伴高度微卫星不稳定性提示免疫原性,伴大量活化的肿瘤浸润淋巴细胞;而聚合酶 ε 核酸外切酶突变伴超高肿瘤突变负荷则提示相对静默的免疫表型。
  • 异质性基因组-免疫相互作用反映在新抗原呈递与耗竭、免疫检查点表达、PD-1/PD-L1 相互作用及 T 细胞对帕博利珠单抗的反应性差异上。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tumor genetic testing is indispensable in the management of primary and metastatic colorectal cancer (CRC), yet the indications for genomics-guided precision medicine and immunotherapy must be better understood and defined. METHODS: We prospectively sequenced tumors from 869 Chinese patients with CRC by a large panel and evaluated the clinical significance of single-gene somatic mutations and co-occurring events in metastatic CRC, as well as their functional effects and tumorigenic mechanisms. We systematically assessed the heterogeneity of the tumor immune microenvironment in different genomic contexts through the combined analysis of Immunoscore, multiplex immunostaining, whole-exome sequencing, transcriptome, and single-cell sequencing. RESULTS: Single-gene somatic mutations in BRAF or RBM10 were associated with shorter progression-free survival in patients with metastatic CRC. Functional studies suggested RBM10 acts as a tumor suppressor in CRC development. Co-mutations of KRAS/AMER1 or KRAS/APC were enriched in the metastatic cohort, which had poor progression-free survival and did not benefit from bevacizumab due to accelerated drug metabolism. Forty patients (4.6%) carried pathogenic or likely pathogenic germline alterations in the DNA damage repair pathway and 37.5% of these tumors had secondary-hit events with loss of heterozygosity or biallelic alterations. A high tumor insertion or deletion burden with high microsatellite instability suggested immunogenicity with numerous activated tumor-infiltrating lymphocytes, whereas polymerase epsilon exonuclease mutation with ultrahigh tumor mutation burden indicated a relatively quiescent immunophenotype. The heterogeneous genomic-immunologic interactions were reflected in the divergent neoantigen presentation and depletion, immune checkpoint expression, PD-1/PD-L1 interaction, and T-cell responsiveness to pembrolizumab. CONCLUSIONS: Our integrated analysis provides insights into CRC prognostic stratification, drug response, and personalized genomics-guided targeted and immunotherapies.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Guo L, Wang Y, Yang W, et al. Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis. Gastroenterology. 2023. PMID: 37146911. doi:10.1053/j.gastro.2023.04.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。